166 related articles for article (PubMed ID: 37321064)
1. Fighting drug-resistant lung cancer by induction of NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated ferroptosis.
Yu J; Zhong B; Zhao L; Hou Y; Ai N; Lu JJ; Ge W; Chen X
Drug Resist Updat; 2023 Sep; 70():100977. PubMed ID: 37321064
[TBL] [Abstract][Full Text] [Related]
2. 2-Methoxy-6-acetyl-7-methyljuglone (MAM) induced programmed necrosis in glioblastoma by targeting NAD(P)H: Quinone oxidoreductase 1 (NQO1).
Yu J; Zhong B; Jin L; Hou Y; Ai N; Ge W; Li L; Liu S; Lu JJ; Chen X
Free Radic Biol Med; 2020 May; 152():336-347. PubMed ID: 32234332
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.
Wu X; Li X; Li Z; Yu Y; You Q; Zhang X
J Med Chem; 2018 Dec; 61(24):11280-11297. PubMed ID: 30508483
[TBL] [Abstract][Full Text] [Related]
4. NAD(P)H Quinone Oxidoreductase-1 Expression Promotes Self-Renewal and Therapeutic Resistance in Non-Small Cell Lung Cancer.
Madajewski B; Boatman MA; Martinez I; Carter JH; Bey EA
Genes (Basel); 2023 Feb; 14(3):. PubMed ID: 36980879
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Lung Cancer by 2-Methoxy-6-Acetyl-7-Methyljuglone Through Induction of Necroptosis by Targeting Receptor-Interacting Protein 1.
Sun W; Yu J; Gao H; Wu X; Wang S; Hou Y; Lu JJ; Chen X
Antioxid Redox Signal; 2019 Jul; 31(2):93-108. PubMed ID: 30556404
[No Abstract] [Full Text] [Related]
6. Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of Drug-Resistant Non-small-Cell Lung Cancer.
Zhang K; Wang K; Zhang X; Qian Z; Zhang W; Zheng X; Wang J; Jiang Y; Zhang W; Lu Z; Hao H; Jiang S
J Med Chem; 2022 Jun; 65(11):7746-7769. PubMed ID: 35640078
[TBL] [Abstract][Full Text] [Related]
7. C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.
Takakuwa O; Oguri T; Ozasa H; Uemura T; Kunii E; Kasai D; Miyazaki M; Maeno K; Sato S
J Thorac Oncol; 2011 Nov; 6(11):1826-32. PubMed ID: 21964527
[TBL] [Abstract][Full Text] [Related]
8. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
Bey EA; Bentle MS; Reinicke KE; Dong Y; Yang CR; Girard L; Minna JD; Bornmann WG; Gao J; Boothman DA
Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11832-7. PubMed ID: 17609380
[TBL] [Abstract][Full Text] [Related]
9. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
Huang X; Dong Y; Bey EA; Kilgore JA; Bair JS; Li LS; Patel M; Parkinson EI; Wang Y; Williams NS; Gao J; Hergenrother PJ; Boothman DA
Cancer Res; 2012 Jun; 72(12):3038-47. PubMed ID: 22532167
[TBL] [Abstract][Full Text] [Related]
10. 2-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
Zhang X; Bian J; Li X; Wu X; Dong Y; You Q
Eur J Med Chem; 2017 Sep; 138():616-629. PubMed ID: 28710963
[TBL] [Abstract][Full Text] [Related]
11. Suppression of NAD(P)H-quinone oxidoreductase 1 enhanced the susceptibility of cholangiocarcinoma cells to chemotherapeutic agents.
Zeekpudsa P; Kukongviriyapan V; Senggunprai L; Sripa B; Prawan A
J Exp Clin Cancer Res; 2014 Jan; 33(1):11. PubMed ID: 24460787
[TBL] [Abstract][Full Text] [Related]
12. Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLC.
Madajewski B; Boatman MA; Chakrabarti G; Boothman DA; Bey EA
Mol Cancer Res; 2016 Jan; 14(1):14-25. PubMed ID: 26553038
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of wild-type p53 by small molecule-induced elevation of NQO1 in non-small cell lung cancer cells.
Yu H; Gao HY; Guo H; Wang GZ; Yang YQ; Hu Q; Liang LJ; Zhao Q; Xie DW; Rao Y; Zhou GB
Acta Pharmacol Sin; 2022 Mar; 43(3):692-702. PubMed ID: 34035487
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
[TBL] [Abstract][Full Text] [Related]
15. An NQO1-initiated and p53-independent apoptotic pathway determines the anti-tumor effect of tanshinone IIA against non-small cell lung cancer.
Liu F; Yu G; Wang G; Liu H; Wu X; Wang Q; Liu M; Liao K; Wu M; Cheng X; Hao H
PLoS One; 2012; 7(7):e42138. PubMed ID: 22848731
[TBL] [Abstract][Full Text] [Related]
16. Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells.
Buranrat B; Prawan A; Kukongviriyapan U; Kongpetch S; Kukongviriyapan V
World J Gastroenterol; 2010 May; 16(19):2362-70. PubMed ID: 20480521
[TBL] [Abstract][Full Text] [Related]
17. A novel strategy for glioblastoma treatment by induction of noptosis, an NQO1-dependent necrosis.
Zhong B; Yu J; Hou Y; Ai N; Ge W; Lu JJ; Chen X
Free Radic Biol Med; 2021 Apr; 166():104-115. PubMed ID: 33600944
[TBL] [Abstract][Full Text] [Related]
18. Synergistic enhancement of antitumor effect of β-Lapachone by photodynamic induction of quinone oxidoreductase (NQO1).
Lamberti MJ; Vittar NB; da Silva Fde C; Ferreira VF; Rivarola VA
Phytomedicine; 2013 Aug; 20(11):1007-12. PubMed ID: 23746950
[TBL] [Abstract][Full Text] [Related]
19. Sulindac compounds facilitate the cytotoxicity of β-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells.
Kung HN; Weng TY; Liu YL; Lu KS; Chau YP
PLoS One; 2014; 9(2):e88122. PubMed ID: 24505400
[TBL] [Abstract][Full Text] [Related]
20. Regulation of MUC5AC expression by NAD(P)H:quinone oxidoreductase 1.
Zheng S; Byrd AS; Fischer BM; Grover AR; Ghio AJ; Voynow JA
Free Radic Biol Med; 2007 May; 42(9):1398-408. PubMed ID: 17395013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
